Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue in Early Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Septic shock diagnosis, according to the Sepsis-3 consensus.~* Prior adequate fluid resuscitation according to dynamic predictors of volume responsiveness.~* More than 6 h and less than 24 h of norepinephrine requirement to maintain a mean arterial pressure ≥65 mmHg.~Exclusion Criteria:~* Age \< 18 years.~* Pregnancy.~* Not expected to survive 48 hours.~* Presence or high suspicion of concurrent hemorrhagic, obstructive or hypovolemic shock.~* Personal or familiar history of glucose-6-phosphate dehydrogenase deficiency.~* Allergic to methylene blue, phenothiazines, or food dyes.~* Recent intake (4-weeks) of selective serotonin re-uptake inhibitors.~* Refusal of the patient or decision maker to enroll in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: PLACEBO_COMPARATOR): Placebo
- Methylene blue (Type: EXPERIMENTAL): Methylene blue

Based on this trial design, predict the completion outcome and termination type (if applicable).